Corcept Therapeutics (CORT) Gross Margin (2012 - 2026)
Corcept Therapeutics (CORT) posted Gross Margin of 98.41% for Q2 2026, little changed sequentially from 98.25% in Q1 2026, and up 18.0% YoY from 83.4% in Q2 2025.
Powered by 
Analysis
Corcept Therapeutics (CORT) Gross Margin (2012 - 2026) Analysis & Trends
Corcept Therapeutics has reported Gross Margin for 15 years, with the latest figure at 98.41% in Q2 2026.
- Quarterly Gross Margin rose 18.0% year-over-year to 98.41% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 98.3% (down 7.0% YoY) and the FY2025 annual result came in at 98.3%, down 9.0% from the prior year.
- Gross Margin steadied at 98.41% in Q2 2026 per CORT's latest filing, from 98.25% in the prior quarter.
- Over five years, Gross Margin peaked at 98.74% in Q4 2025 and troughed at 97.79% in Q3 2025.
- A 5-year average of 98.48% and a median of 98.52% in 2022 frame the typical range for Gross Margin.
- The widest YoY moves for Gross Margin: up 37 bps in 2025, down 64 bps in 2025.
- Over 5 years, Gross Margin stood at 98.56% in 2022, then grew by 0 bps to 98.61% in 2023, then slipped by 0 bps to 98.37% in 2024, then grew by 0 bps to 98.74% in 2025, then declined by 0 bps to 98.41% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 98.41%, 98.25%, and 98.74% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Corcept Therapeutics | 11.76 Bn | 11.46 Bn | 252.09 Mn | 98.41% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 98.41% |
| Mar 31, 2026 | 98.25% |
| Dec 31, 2025 | 98.74% |
| Sep 30, 2025 | 97.79% |
| Jun 30, 2025 | 98.23% |
| Mar 31, 2025 | 98.47% |
| Dec 31, 2024 | 98.37% |
| Sep 30, 2024 | 98.43% |
| Jun 30, 2024 | 98.46% |
| Mar 31, 2024 | 98.27% |
| Dec 31, 2023 | 98.61% |
| Sep 30, 2023 | 98.67% |
| Jun 30, 2023 | 98.66% |
| Mar 31, 2023 | 98.69% |
| Dec 31, 2022 | 98.56% |
| Sep 30, 2022 | 98.68% |
| Jun 30, 2022 | 98.73% |
| Mar 31, 2022 | 98.67% |
| Dec 31, 2021 | 98.63% |
| Sep 30, 2021 | 98.67% |